Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:LIFE

aTyr Pharma (LIFE) Stock Price, News & Analysis

aTyr Pharma logo

About aTyr Pharma Stock (NASDAQ:LIFE)

Key Stats

Today's Range
N/A
50-Day Range
$1.57
$2.07
52-Week Range
N/A
Volume
269,400 shs
Average Volume
514,103 shs
Market Capitalization
$131.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.50
Consensus Rating
Buy

Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

aTyr Pharma Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
29th Percentile Overall Score

LIFE MarketRank™: 

aTyr Pharma scored higher than 29% of companies evaluated by MarketBeat, and ranked 811th out of 949 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    aTyr Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    aTyr Pharma has received no research coverage in the past 90 days.

  • Read more about aTyr Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for aTyr Pharma are expected to grow in the coming year, from ($0.89) to ($0.74) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of aTyr Pharma is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of aTyr Pharma is -2.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Short Interest

    There is no current short interest data available for LIFE.
  • Dividend Yield

    aTyr Pharma does not currently pay a dividend.

  • Dividend Growth

    aTyr Pharma does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for LIFE.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for aTyr Pharma this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, aTyr Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 3.70% of the stock of aTyr Pharma is held by insiders.

  • Percentage Held by Institutions

    61.72% of the stock of aTyr Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about aTyr Pharma's insider trading history.
Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Stock News Headlines

A Simple Trading Strategy You Should Know
It’s no secret, I love big, juicy options trades. But when you’re chasing the BIG fish, you gotta have a way to target some steady, consistent returns in there as well. Check out the $100 Challenge This Chris Pulver, he’s isolated a way for everyday folks to target $100-$150 a day in the stock market, starting with just $1,000 or so. And while we cannot promise future returns or against losses, It’s the perfect supplement to more aggressive options strategies… And right now, everyone needs more cash in this economy.
aTyr Pharma initiated with a Buy at Lucid Capital
See More Headlines

LIFE Stock Analysis - Frequently Asked Questions

aTyr Pharma, Inc. (NASDAQ:LIFE) issued its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.01. The biotechnology company had revenue of $0.24 million for the quarter, compared to analyst estimates of $0.11 million.

aTyr Pharma's stock reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

aTyr Pharma (LIFE) raised $76 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup acted as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

Based on aggregate information from My MarketBeat watchlists, some other companies that aTyr Pharma investors own include Tesla (TSLA), Plug Power (PLUG), Meta Platforms (META), NVIDIA (NVDA), SCYNEXIS (SCYX), Ford Motor (F) and NIO (NIO).

Company Calendar

Last Earnings
5/02/2024
Today
12/23/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Current Symbol
NASDAQ:LIFE
CUSIP
53217V10
Employees
56
Year Founded
2005

Price Target and Rating

Average Stock Price Target
$25.50
High Stock Price Target
$35.00
Low Stock Price Target
$16.00
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-50,390,000.00
Pretax Margin
-9,172.11%

Debt

Sales & Book Value

Annual Sales
$350,000.00
Book Value
$1.54 per share

Miscellaneous

Free Float
66,458,000
Market Cap
$131.12 million
Optionable
Optionable
Beta
1.19

Social Links

The 10 Best AI Stocks to Own in 2025 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

This page (NASDAQ:LIFE) was last updated on 12/23/2024 by MarketBeat.com Staff
From Our Partners